Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Apr 30, 2010 12:37pm
336 Views
Post# 17049175

Positive GPRO call

Positive GPRO callI am surprised that there has not been any talk about the positive comments that Gen-Probe made on their call last night in respect to PCA3. I understand that we have heard it all before, but we are getting close to the sweet spot. At some point it has to be reflected in the share price. I am shocked and surprised that we are not sitting at a new 52 week high.
     I did not take notes, but Panther is on tract to launch in Europe this year. (I only bring this up because this will really help future pca3 sales explode)
     In respect to PCA3 they talked about how well sales have been progressing and that they have completed the FDA trial and plan to file in the 3rd quarter of this year.
They spoke about the positive GSK trial news and about the recent clinical trial (that has went unnoticed by investors)
I am not sure what it will take for us to gain some momentum, but once it happens we could be in the $5.00 range quickly. Its clear that the share price is not following the progression I have mapped out in my mind but as long as it finds its way, I'll be happy.
Bullboard Posts